Lew Sze Yuen, Phang Michael Weng Lok, Chong Pit Shan, Roy Jaydeep, Poon Chi Him, Yu Wing Shan, Lim Lee Wei, Wong Kah Hui
Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China.
Pharmaceuticals (Basel). 2022 Jun 19;15(6):764. doi: 10.3390/ph15060764.
Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of rare neurodegenerative inherited disorders. The resulting motor incoordination and progressive functional disabilities lead to reduced lifespan. There is currently no cure for ARCAs, likely attributed to the lack of understanding of the multifaceted roles of antioxidant defense and the underlying mechanisms. This systematic review aims to evaluate the extant literature on the current developments of therapeutic strategies that target oxidative stress for the management of ARCAs. We searched PubMed, Web of Science, and Science Direct Scopus for relevant peer-reviewed articles published from 1 January 2016 onwards. A total of 28 preclinical studies fulfilled the eligibility criteria for inclusion in this systematic review. We first evaluated the altered cellular processes, abnormal signaling cascades, and disrupted protein quality control underlying the pathogenesis of ARCA. We then examined the current potential therapeutic strategies for ARCAs, including aromatic, organic and pharmacological compounds, gene therapy, natural products, and nanotechnology, as well as their associated antioxidant pathways and modes of action. We then discussed their potential as antioxidant therapeutics for ARCAs, with the long-term view toward their possible translation to clinical practice. In conclusion, our current understanding is that these antioxidant therapies show promise in improving or halting the progression of ARCAs. Tailoring the therapies to specific disease stages could greatly facilitate the management of ARCAs.
常染色体隐性遗传性小脑共济失调(ARCAs)是一组异质性罕见的神经退行性遗传疾病。由此导致的运动不协调和进行性功能残疾会缩短寿命。目前尚无治愈ARCAs的方法,这可能归因于对抗氧化防御的多方面作用及其潜在机制缺乏了解。本系统评价旨在评估现有文献中针对氧化应激的治疗策略在ARCAs管理方面的当前进展。我们在PubMed、科学网和科学Direct Scopus中检索了自2016年1月1日起发表的相关同行评议文章。共有28项临床前研究符合纳入本系统评价的资格标准。我们首先评估了ARCAs发病机制中细胞过程的改变、异常信号级联反应和蛋白质质量控制的破坏。然后,我们研究了ARCAs目前潜在的治疗策略,包括芳香族、有机和药理化合物、基因治疗、天然产物和纳米技术,以及它们相关的抗氧化途径和作用方式。接着,我们讨论了它们作为ARCAs抗氧化治疗方法的潜力,并从长远角度展望其转化为临床实践的可能性。总之,我们目前的认识是,这些抗氧化疗法在改善或阻止ARCAs进展方面显示出前景。根据特定疾病阶段调整治疗方法可极大地促进ARCAs的管理。